Making Treatment Decisions About Discontinuing TKIs in Chronic Myeloid Leukemia
Researchers are assessing the value and safety of discontinuing TKI therapy in patients with chronic phase CML who have achieved deep molecular response.
Lauren Dembeck, PhD
Contributing Writer https://www.hematologyadvisor.com
Lauren Dembeck is a freelance science and medical writer and a contributing author for the Haymarket Medical Network. She holds a BS in biology and a BA in foreign languages from West Virginia University and a PhD in genetics from North Carolina State University. Prior to freelance writing, Lauren was a postdoctoral researcher at the Okinawa Institute of Science and Technology in Japan, where she studied developmental neurobiology. You can find more of her writing at https://laurendembeck.com/.
